Reading this on a mobile device? Try our optimized mobile version here:

June 24, 2013
News for diabetes health professionals
Sign up|Forward|Archive|Advertise

Diabetes in Focus 
  • Intensive therapy for type 1 diabetes shows long-term benefits
    Type 1 diabetes patients on intensive treatment had a 46% reduced risk of retinopathy, a 39% lower risk of microalbuminuria and a 61% lower risk of macroalbuminuria over 18 years than those who received standard care, a study presented at the ADA 73rd Scientific Sessions indicated. Researchers also noted a 39% lower risk of focal laser therapy and a 48% lower risk of any ocular surgery in the intensive treatment group compared with the controls. MedPage Today (free registration) (6/23) LinkedInFacebookTwitterEmail this Story
  • Phone intervention improves A1C in urban diabetes patients
    A study of adult diabetes patients in the South Bronx showed those who received a phone-based intervention from community-based health educators had a 0.6% lower A1C at one year than those in the control group. Patients whose A1C was in the greater than 7% to 9% tier at baseline attained little improvement following intervention, while their counterparts who did not receive treatment had slightly elevated A1C, researchers reported at the ADA 73rd Scientific Sessions. Medscape (free registration) (6/22) LinkedInFacebookTwitterEmail this Story
  • Lilly's dulaglutide outperforms widely used diabetes drugs in trials
    Data from three late-stage trials presented at the ADA 73rd Scientific Sessions showed patients injected with Eli Lilly and Co.'s experimental GLP-1 receptor agonist dulaglutide experienced sustained reductions in blood glucose and lost more weight compared with patients who took generic metformin, Bristol-Myers Squibb's Byetta or Merck & Co.'s Januvia. Lilly plans to submit dulaglutide for U.S. approval later this year. Reuters (6/22) LinkedInFacebookTwitterEmail this Story
  • Study: Workers with DME, retinopathy miss more work
    Data presented at the ADA 73rd Scientific Sessions revealed employee absenteeism was greater in those with diabetic macular edema or diabetic retinopathy than in workers who did not have the conditions. "This analysis shows the detrimental impact of [diabetic macular edema] and [diabetic retinopathy] on employee absenteeism, particularly those employees who depend on eyesight for their jobs, such as commercial drivers," researchers noted. Healio/Endocrine Today (6/22) LinkedInFacebookTwitterEmail this Story
Support DiabetesPro SmartBrief
DiabetesPro SmartBrief is the daily e-news resource for 31,000 influential leaders in diabetes care. E-mail Aaron Kern for more information on advertising.
Nutrition & Wellness 
Practice Update 
  • ONC unveils HIT Web page for long-term care providers
    The ONC has launched a new Web page that gives long-term care providers information about federal health IT initiatives that could be beneficial to them. These providers don't qualify for the EHR incentive initiatives, although they do contribute to enhanced care transition processes. One initiative mentioned on the site is the Beacon Community programs that promote patient data sharing between nursing facilities and health information exchanges with or without the use of EHRs. Health Data Management (6/20) LinkedInFacebookTwitterEmail this Story
Trends & Technology 
  • New app allows patients to look at medical procedures' costs
    A free smartphone application called FH Healthcare Cost Estimator was unveiled by FAIR Health to help patients calculate the cost of medical procedures. The tool also provides average cost data in several other areas, such as diagnostic testing, office visits and emergency treatments, whether in or out of a patient's health insurance network. (6/21) LinkedInFacebookTwitterEmail this Story
ADA Scientific Sessions 
  • Meeting the challenge of the exploding diabetes epidemic
    To help meet the challenge of the "tsunami of diabetes," ADA President, Medicine & Science Dr. John E. Anderson announced the Pathway to Stop Diabetes Initiative, designed to radically alter diabetes research. The vision of the initiative is to "find a new generation of brilliant scientists ... and equip them with the freedom, autonomy, and resources to set them off on the road to great new discoveries," he said. ADA Diabetes Dispatch (2013) LinkedInFacebookTwitterEmail this Story
  • Banting lecturer discusses genetics of diabetes
    In a lecture yesterday, Dr. Graeme I. Bell discussed his work with a family of genes related to maturity-onset diabetes of the young, or MODY. Dr. Bell was this year's recipient of the Banting Medal for Scientific Achievement. He emphasized that genetic testing can be cost-effective if it allows providers to preselect patients for testing to increase pickup rates. "You are affecting the health care of not just one individual but of families and extended families. We cannot lose sight of that," he said. ADA Diabetes Dispatch (2013) LinkedInFacebookTwitterEmail this Story
Conference Information 
  • ADA Exhibits -- Hall F2 (Booths 747 and 759)
    Today (10 a.m.-2 p.m.) is your last day to visit the ADA Exhibit in Booth 747 to find out about our latest clinical and patient resources. Visit the Stop Diabetes Pavilion in Booth 759 to find out how you can Join the Millions® in the movement to Stop Diabetes®. Turn in your completed Diabetes Bingo cards for a chance to win an ADA Prize Pack! LinkedInFacebookTwitterEmail this Story
  • Get the 73rd Scientific Sessions app!
    Put the Scientific Sessions in the palm of your hand! Use ADA's Scientific Sessions app for on-the-go access to meeting information on your smartphone or other handheld device. Features include a customizable calendar and itinerary builder, meeting abstracts, exhibitor listing with interactive booth map, social media interface and special meeting alerts. Get the app. LinkedInFacebookTwitterEmail this Story
  • Diabetes Dispatch Newspaper -- Monday edition
    Read the Monday edition of the 73rd Scientific Sessions to learn about what's happening at the meeting this year. Read it now. LinkedInFacebookTwitterEmail this Story
Above all be of single aim; have a legitimate and useful purpose, and devote yourself unreservedly to it."
--James Allen,
British writer
LinkedInFacebookTwitterEmail this Story

Product announcements appearing in SmartBrief are paid advertisements and do not reflect actual DiabetesPro endorsements. The news reported in SmartBrief does not necessarily reflect the official position of DiabetesPro.
Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director: Aaron Kern (202) 407-7866
 Recent DiabetesPro SmartBrief Issues:   Lead Editor: Kathryn Doherty
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information